263 related articles for article (PubMed ID: 25663618)
1. Pharmacokinetics of mycophenolate sodium co-administered with tacrolimus in the first year after renal transplantation.
Sobiak J; Resztak M; Głyda M; Szczepaniak P; Chrzanowska M
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):331-8. PubMed ID: 25663618
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
de Winter BC; van Gelder T; Sombogaard F; Shaw LM; van Hest RM; Mathot RA
J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early-phase post-kidney transplantation.
Stracke S; Shipkova M; Mayer J; Keller F; Zarghom A; Yang L; Henne-Bruns D; Wieland E
Clin Transplant; 2012; 26(1):57-66. PubMed ID: 21299636
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
[TBL] [Abstract][Full Text] [Related]
6. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil.
Kuypers DR; Vanrenterghem Y; Squifflet JP; Mourad M; Abramowicz D; Oellerich M; Armstrong V; Shipkova M; Daems J
Ther Drug Monit; 2003 Oct; 25(5):609-22. PubMed ID: 14508385
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
[TBL] [Abstract][Full Text] [Related]
8. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.
Naito T; Shinno K; Maeda T; Kagawa Y; Hashimoto H; Otsuka A; Takayama T; Ushiyama T; Suzuki K; Ozono S
Biol Pharm Bull; 2006 Feb; 29(2):275-80. PubMed ID: 16462031
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
Huang HF; Yao X; Chen Y; Xie WQ; Shen-Tu JZ; Chen JH
Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
[TBL] [Abstract][Full Text] [Related]
10. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.
Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K
Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of mycophenolate mofetil.
Bullingham RE; Nicholls AJ; Kamm BR
Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity.
Shah T; Tellez-Corrales E; Yang JW; Qazi Y; Wang J; Wilson J; Hutchinson I; Min DI
Ther Drug Monit; 2011 Feb; 33(1):45-9. PubMed ID: 21099740
[TBL] [Abstract][Full Text] [Related]
13. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
[TBL] [Abstract][Full Text] [Related]
14. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
Xu L; Cai M; Shi BY; Li ZL; Li X; Jin HL
Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
Staatz CE; Tett SE
Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
[TBL] [Abstract][Full Text] [Related]
17. In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil.
Morissette P; Albert C; Busque S; St-Louis G; Vinet B
Ther Drug Monit; 2001 Oct; 23(5):520-5. PubMed ID: 11591897
[TBL] [Abstract][Full Text] [Related]
18. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients.
Graff J; Scheuermann EH; Brandhorst G; Oellerich M; Gossmann J
Ther Drug Monit; 2016 Jun; 38(3):388-92. PubMed ID: 26829599
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Enteric-Coated Mycophenolate Sodium Metabolites in Patients Over 60 Years Old Within the First Year After Renal Transplantation.
Sobiak J; Głyda M; Chrzanowska M
Transplant Proc; 2021 Apr; 53(3):1001-1004. PubMed ID: 33246587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
